中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2008年
2期
109-113
,共5页
吴正升%吴强%丁向东%王红群%沈玉先%方圣云
吳正升%吳彊%丁嚮東%王紅群%瀋玉先%方聖雲
오정승%오강%정향동%왕홍군%침옥선%방골운
乳腺肿瘤%爪蟾蛋白质类%受体,雌激素%肿瘤转移%预后
乳腺腫瘤%爪蟾蛋白質類%受體,雌激素%腫瘤轉移%預後
유선종류%조섬단백질류%수체,자격소%종류전이%예후
Breast neoplasms%Xenopus proteins%Receptors,estrogen%Neoplasm metastasis%Prognosis
目的 研究转移诱导蛋白AGR2在人乳腺癌中表达和意义及其与患者预后的关系.方法 采用组织芯片,应用免疫组织化学方法检测160例乳腺癌和20例乳腺良性病变组织AGR2表达,以及乳腺癌ERα、PR和HER2表达状况,并用Kaplan-Meier曲线法和Log-rank检验对有随访资料的127例进行与AGR2的相关性分析.结果 乳腺癌AGR2表达量较乳腺良性病变显著性增高(68.3%和25.0%,P<0.01);AGR2表达与乳腺癌组织学分级呈负相关(P<0.05),与乳腺癌ERα和PR表达呈正相关(分别为P<0.05和P<0.01);Logistic回归模型显示AGR2和TNM分期是ERa阳性乳腺癌淋巴结转移重要的影响因子(均P<0.01);Kaplan-Meier生存曲线显示ERα阳性乳腺癌患者中,AGR2阳性患者总生存率和无复发生存率均显著低于阴性患者(均P<0.01),COX比例风险模型分析也证实AGR2蛋白表达是ERα阳性乳腺癌患者独立的预后影响因子(P<0.01).结论 AGR2表达异常可能参与了乳腺癌的发生、发展过程,该机制可能部分依赖雌激素受体途径发挥其诱导肿瘤转移作用.AGR2可能是一个潜在的分子标记物,对雌激素受体阳性乳腺癌患者的预后评估有一定提示作用.
目的 研究轉移誘導蛋白AGR2在人乳腺癌中錶達和意義及其與患者預後的關繫.方法 採用組織芯片,應用免疫組織化學方法檢測160例乳腺癌和20例乳腺良性病變組織AGR2錶達,以及乳腺癌ERα、PR和HER2錶達狀況,併用Kaplan-Meier麯線法和Log-rank檢驗對有隨訪資料的127例進行與AGR2的相關性分析.結果 乳腺癌AGR2錶達量較乳腺良性病變顯著性增高(68.3%和25.0%,P<0.01);AGR2錶達與乳腺癌組織學分級呈負相關(P<0.05),與乳腺癌ERα和PR錶達呈正相關(分彆為P<0.05和P<0.01);Logistic迴歸模型顯示AGR2和TNM分期是ERa暘性乳腺癌淋巴結轉移重要的影響因子(均P<0.01);Kaplan-Meier生存麯線顯示ERα暘性乳腺癌患者中,AGR2暘性患者總生存率和無複髮生存率均顯著低于陰性患者(均P<0.01),COX比例風險模型分析也證實AGR2蛋白錶達是ERα暘性乳腺癌患者獨立的預後影響因子(P<0.01).結論 AGR2錶達異常可能參與瞭乳腺癌的髮生、髮展過程,該機製可能部分依賴雌激素受體途徑髮揮其誘導腫瘤轉移作用.AGR2可能是一箇潛在的分子標記物,對雌激素受體暘性乳腺癌患者的預後評估有一定提示作用.
목적 연구전이유도단백AGR2재인유선암중표체화의의급기여환자예후적관계.방법 채용조직심편,응용면역조직화학방법검측160례유선암화20례유선량성병변조직AGR2표체,이급유선암ERα、PR화HER2표체상황,병용Kaplan-Meier곡선법화Log-rank검험대유수방자료적127례진행여AGR2적상관성분석.결과 유선암AGR2표체량교유선량성병변현저성증고(68.3%화25.0%,P<0.01);AGR2표체여유선암조직학분급정부상관(P<0.05),여유선암ERα화PR표체정정상관(분별위P<0.05화P<0.01);Logistic회귀모형현시AGR2화TNM분기시ERa양성유선암림파결전이중요적영향인자(균P<0.01);Kaplan-Meier생존곡선현시ERα양성유선암환자중,AGR2양성환자총생존솔화무복발생존솔균현저저우음성환자(균P<0.01),COX비례풍험모형분석야증실AGR2단백표체시ERα양성유선암환자독립적예후영향인자(P<0.01).결론 AGR2표체이상가능삼여료유선암적발생、발전과정,해궤제가능부분의뢰자격소수체도경발휘기유도종류전이작용.AGR2가능시일개잠재적분자표기물,대자격소수체양성유선암환자적예후평고유일정제시작용.
Objective To investigate the expression of a novel metastasis-inducing protein human anterior gradient-2(AGR2)in breast cancer and its clinical and prognostic significance.Methods AGR2 expression was assessed in 160 cases of breast cancer and 20 cases of benign breast diseases by immunohistochemistry using tissue chip technology.In addition the expression of Erα,PR and c-erbB-2 in breast cancer was also evaluated.Follow-up information of 5-year duration was available in 127 patients with breast cancer.Kaplan-Meier analysis and COX regression model were used to analyze the correlation between AGR2 expression and the follow-up clinical data.Results The expression of AGR2 was significantly higher in breast cancers than that in benign diseases(68.3%vs.25.O%,P<0.01).There was a negative correlation between AGR2 expression and the histological grade of breast cancer(P<0.05),whereas positive correlations was found between the expression of AGR2 and Erα(P<0.05),and between the expression of AGR2 and PR(P<0.01).In the subgroup of Erα-positive breast cancer,Logistic regression model demonstrated AGR2 and TNM stage were important factors affecting lymph node metastasis(both P<0.01).Kaplan-Meier analysis demonstrated that a positive expression of AGR2 was associated with poor overall survival and relapse-free survival(both P<0.01).Moreover,COX regression model confirmed the expression of AGR2 as an independent prognostic factor among patients with Erα-positive breast cancer (P<0.01).Conclusions The abnormal expression of AGR2 may play a role in the pathogenesis and progression of breast cancer.The metastasis-inducing capability of AGR2 may be partly regulated through the ER pathway.Therefore,AGR2 may be a useful molecular marker for prognostication for patient with hormone-responsive breast cancer.